论文部分内容阅读
目的探讨β受体阻滞剂局部外用对婴幼儿血管瘤的疗效及安全性的研究现状,为临床提供循证医学依据及参考。方法在中英文数据库中检索截至2014年6月的所有关于β受体阻滞剂局部外用治疗婴幼儿血管瘤的文献进行Meta分析。结果利用上述检索策略共检出76篇相关文献,最终纳入文献8篇。(1)β受体阻滞剂局部外用治疗组效果高于安慰剂生臣/观察组,差异有显著性(P<0.00001)。(2)β受体阻滞剂局部外用组疗效和口服普萘洛尔组疗效差异无显著性(P=0.41)。(3)β受体阻滞剂局部外用组全身不良反应少于口服普萘洛尔组,差异有显著性(P=0.002)。结论β受体阻滞剂局部外用疗效和口服普萘洛尔治疗婴幼儿血管瘤无显著差异,全身不艮反应相对更少。
Objective To investigate the efficacy and safety of beta-blocker topical application on infantile hemangiomas, and to provide evidence-based medical evidence and references for clinical practice. Methods Meta-analysis was conducted in the Chinese and English databases of all literatures on topical topical beta-blocker therapy for infantile hemangiomas as of June 2014. Results A total of 76 related articles were detected using the above search strategy, and finally included in the literature. (1) The effect of topical beta-blocker topical treatment was higher than that of placebo/observation group, and the difference was significant (P < 0.00001). (2) There was no significant difference in efficacy between the topical beta-blocker topical group and oral propranolol group (P=0.41). (3) There was a significant difference in systemic adverse reactions in the beta-blocker topical group compared with oral propranolol group (P=0.002). Conclusion There is no significant difference in the efficacy of topical beta-blocker therapy and oral propranolol in the treatment of hemangiomas in infants and young children, and there is relatively less systemic insufficiency.